Chronic pain biotech co-founded by Vivek Ramaswamy joins reverse merger train
A California biotech with a chronic pain drug that's long been approved in Italy, but not the US, is going onto the public markets through the increasingly popular reverse merger route. Ambros ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.